Результати пошуку - Paz Ribas

  • Показ 1 - 8 результатів із 8
Уточнити результати
  1. 1
    Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

    Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a M... за авторством Margarita Blanes, Juan José Lahuerta, José D. González, Paz Ribas, Carlos Solano, Adrián Alegre, Joan Bladé, Jesús F. San Miguel, Miguel Á. Sanz, Javier de la Rubia

    Опубліковано 2012
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  2. 2
    Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients

    Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients за авторством Enric Carreras, Laura Rosiñol, María José Terol, Adrián Alegre, Felipe de Arriba, José García‐Laraña, José Belló, Raimundo García, Ángel León, Rafael Martínez, María Jesús Peñarrubia, Concha Poderós, Paz Ribas, Josep‐María Ribera, Jesús F. San Miguel, Joan Bladé, Juan José Lahuerta

    Опубліковано 2007
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicente... за авторством Verónica González‐Calle, Paula Rodríguez‐Otero, Anna Sureda, Felipe de Arriba, Marta Reinoso, Paz Ribas, Ana Pilar González-Rodríguez, Yolanda Campos, Albert Oriol, Joaquín Martínez‐López, Marta Sonia González, Miguel‐Teodoro Hernández, Maialen Sirvent, María‐Teresa Cedena, Noemí Puig, Bruno Paiva, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel, María‐Victoria Mateos

    Опубліковано 2024
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  4. 4
    Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

    Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Itha... за авторством María‐Victoria Mateos, Paula Rodríguez‐Otero, Youngil Koh, Joaquín Martínez‐López, Gurdeep Parmar, H. Miles Prince, Hang Quach, Paz Ribas, Emil Hermansen, Vânia Hungria, Sevgi Kalayoğlu Beşışık, Jin Seok Kim, Xavier Leleu, Valdas Pečeliūnas, Fredrik Schjesvold, Ömür Gökmen Sevindik, Т Е Лаврова, Franck Dubin, Christine Devisme, Lucie Lepine, Sandrine Macé, Mony Morisse, Irene M. Ghobrial

    Опубліковано 2022
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  5. 5
    Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

    Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results... за авторством Sandy W. Wong, Noffar Bar, Laura París, Craig C. Hofmeister, Markus Hansson, Armando Santoro, María‐Victoria Mateos, Paula Rodríguez‐Otero, Johan Lund, Cristina Encinas, Andrew J. Yee, Albert Oriol, Claudio Cerchione, Javier de la Rubia, Barbara Ferstl, Kristina Carlson, Paz Ribas, Arancha Bermúdez, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús F. San Miguel, Luciano J. Costa

    Опубліковано 2022
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

    Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study за авторством María‐Victoria Mateos, JoséM. Hernández, M.B. Gómez Hernández, Norma C. Gutiérrez, Luis Palomera, M. Fuertes, Joaquı́n Dı́az-Mediavilla, Juan José Lahuerta, Javier de la Rubia, María José Terol, Ana Sureda, Joan Bargay, Paz Ribas, Felipe de Arriba, Adrián Alegre, Albert Oriol, Dolores Carrera, José García‐Laraña, Ramón García‐Sánz, Joan Bladé, Felipe Prósper, Gemma Flores‐Mateo, Dixie‐Lee Esseltine, Helgi van de Velde, Jesús F. San Miguel

    Опубліковано 2006
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

    Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refrac... за авторством Noffar Bar, María‐Victoria Mateos, Paz Ribas, Markus Hansson, Laura París, Craig C. Hofmeister, Paula Rodríguez‐Otero, Maria Aranzazu Bermúdez, Thomas G Martin, Armando Santoro, Andrew J. Yee, Maria Creignou, Cristina Encinas Rodriguez, Claudio Cerchione, Javier de la Rubia, Albert Oriol, Heidi Waibel, Britta Besemer, Ethan Thompson, Brian F. Kiesel, Jinjie Chen, Alexander Yaw Fui Chung, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús F. San Miguel, Luciano J. Costa

    Опубліковано 2023
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

    Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study за авторством Fredrik Schjesvold, Meletios Α. Dimopoulos, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Wojciech Legieć, Luděk Pour, Ivan Špıčka, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alekseeva, Antonio Lazzaro, Vladimír Maisnar, Gábor Mikala, Laura Rosiñol, Anna Marina Liberati, Argiris Symeonidis, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A. Bakker, Roman Hájek, María‐Victoria Mateos, Paul G. Richardson, Pieter Sonneveld, Fredrik Schjesvold, Sosana Delimpasi, Paweł Robak, Daniel Coriu, Anna Nikolayeva, Waldemar Tomczak, Luděk Pour, Ivan Špıčka, Meletios Α. Dimopoulos, Tamás Masszi, Vadim Doronin, Jiří Minařík, Galina Salogub, Yulia Alekseeva, Vladimír Maisnar, Gábor Mikala, Laura Rosiñol, Т. С. Константинова, Antonio Lazzaro, Anna Marina Liberati, Argiris Symeonidis, Moshe E. Gatt, Árpád Illés, Haifaa Abdulhaq, Moez Dungarwalla, Sebastian Grosicki, Roman Hájek, Xavier Leleu, Alexander Myasnikov, Paul G. Richardson, Irit Avivi, Dries Deeren, Mercedes Gironella, Miguel Teodoro Hernández‐Garcia, Joaquín Martínez‐López, Muriel Newinger-Porte, Paz Ribas, Olga Samoilova, Éric Voog, Mario Arnao‐Herráiz, Estrella Carrillo‐Cruz, Paolo Corradini, Jyothi Dodlapati, Miquel Granell, Shang‐Yi Huang, Matthew Jenner, Lionel Karlin, Jin Seok Kim, Agnieszka Kopacz, Н. В. Медведева, Chang‐Ki Min, Roberto Mina, Katrin Palk, Ho‐Jin Shin, Sang Kyun Sohn, Pieter Sonneveld, Jason Tache, Αchilles Anagnostopoulos, José-María Arguiñano, Michèle Cavo, Joanne Filicko, Margaret Garnes, Janusz Hałka, Kathrin Herzog-Tzarfati, Natalia Ipatova, Kihyun Kım, Maria‐Theresa Krauth, I. V. Kryuchkova, Mihaela Lazaroiu, Mario Luppi, Andrei Proydakov, Alessandro Rambaldi

    Опубліковано 2022
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: